Translational Research Division

Maureen Handoko, Peng Liu, Kathy Zahs, Miranda Reed

The goal of the work performed by the Translational Division is to use the knowledge gained by the basic scientists in the CMRC to develop strategies that prevent or delay the onset of Alzheimer’s disease. Current projects include the development of a high-throughput behavioral assay to test the effects of selected compounds on cognitive performance in mouse models of Alzheimer’s disease and the development of assays to measure levels of Aß*56 and other potential biomarkers for Alzheimer’s disease in the cerebrospinal fluid, serum, or urine of human subjects.  The results of these studies will guide the design of prevention trials in people.

Faculty and Scientists

• Kathleen Zahs, PhD 

Post-Doctoral Fellows and Research Associates

• Peng Liu, PhD
• Miranda Reed, PhD

Doctoral Candidates

• Maureen Handoko

Collaborating Members

• Derek Hook, PhD
  Institute for Therapeutics Discovery and Development
  Director, High Throughput Screening Core
• Michael Walters, PhD
  Institute for Therapeutics Discovery and Development
  Director, Lead and Probe Discovery:  Evaluation of active compounds from high-throughput screening for their potential as leads for drug discovery or probes of biochemical mechanisms.  Initial optimization of a lead compound's physical properties as it is developed into a potential drug.